PMA device
LOTUS Edge Valve System
Boston Scientific Corporation · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Jul 22, 2019, newest Mar 30, 2021Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
7
Naming "LOTUS Edge"
MAUDE reports
1,077
Brand "LOTUS Edge", since 2015
PubMed studies
15
Mentioning "LOTUS Edge"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing LOTUS Edge Valve System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- LOTUS Edge Valve SystemPMA supplement
P180029-S030 · Decided Mar 30, 2021 · 29 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
- Lotus Edge Valve SystemPMA supplement
P180029-S003 · Decided Dec 6, 2019 · 197 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
- Lotus Edge Valve SystemPMA supplement
P180029-S002 · Decided Jul 22, 2019 · 60 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "LOTUS Edge", any status and sponsor, newest update first.
Boston Scientific CorporationPublic (BSX)
NCT03084510 · 0 participants · Start Feb 28, 2020 · Primary completion Nov 30, 2020
Device: Lotus Edge™ Valve System · For: Stenoses, Aortic Valve
Sites: Beijing, China
Boston Scientific CorporationPublic (BSX)
NCT03618095 · 382 participants · Start Jan 14, 2019 · Primary completion Mar 30, 2021
Device: LOTUS Edge Valve System · For: Aortic Valve Stenosis
Sites: Huntsville, Alabama; Tucson, Arizona; Little Rock, Arkansas · 50 sites in all
- Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve ReplacementPivotal-lookingTerminated
Boston Scientific CorporationPublic (BSX)
NCT02202434 · 1,425 participants · Start Sep 22, 2014 · Primary completion Mar 8, 2017
Device: Lotus Valve System; CoreValve/Evolut R Transcatheter Aortic Valve Replacement System and 1 more · For: Aortic Stenosis
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 58 sites in all
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "LOTUS Edge", and for the whole product code for context.
This brand
1,077 reports: 110 malfunction, 857 injury, 110 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
2124215-2026-31800 · Received Jun 15, 2026 · Event dated Jun 9, 2020
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2124215-2026-29693 · Received Jun 3, 2026 · Event dated Apr 10, 2020
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2124215-2026-29809 · Received Jun 3, 2026 · Event dated Sep 30, 2020
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0728-2021 · Started Nov 17, 2020 · Posted by FDA Jan 9, 2021
Reason given: Failure to execute the visual inspection correctly prior to locking the valve during the deployment process can lead to the inability to release the delivery system.
Cause as FDA categorized it: Device Design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Z-0729-2021 · Started Nov 17, 2020 · Posted by FDA Jan 9, 2021
Reason given: Failure to execute the visual inspection correctly prior to locking the valve during the deployment process can lead to the inability to release the delivery system.
Cause as FDA categorized it: Device Design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Z-0730-2021 · Started Nov 17, 2020 · Posted by FDA Jan 9, 2021
Reason given: Failure to execute the visual inspection correctly prior to locking the valve during the deployment process can lead to the inability to release the delivery system.
Cause as FDA categorized it: Device Design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
3 more recall records with a free account
Published research
The most relevant PubMed records for "LOTUS Edge"[tiab]. The summary above synthesizes these.
- The LOTUS Edge Is Up for a Challenge.
Toggweiler S · JACC Cardiovasc Interv · 2021Editorial, Comment
- A TAV-in-TAV-in-SAV Lifetime Management.
Bianchini E, Linnane M, Sgreva S, et al. · JACC Case Rep · 2026Case Reports
- Surgical explantation of an infected Lotus Edge valve: a case report.
Yanagino Y, Kainuma S, Kawamoto N, et al. · Gen Thorac Cardiovasc Surg Cases · 2024
- The Lotus Valve System: an In-depth Review of the Technology.
Seigerman ME, Nathan A, Anwaruddin S · Curr Cardiol Rep · 2019Review
- The mechanically expandable LOTUS Valve and LOTUS Edge transcatheter aortic valve systems.
Solomonica A, Choudhury T, Bagur R · Expert Rev Med Devices · 2018Review
- Single-Center Experience With the LOTUS Edge Transcatheter Heart Valve.
Medranda GA, Rogers T, Case BC, et al. · Cardiovasc Revasc Med · 2021Letter
- Risk Assessment of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation in Patients With Preexisting Right Bundle Branch Block.
Sugiyama Y, Miyashita H, Yokoyama H, et al. · Am J Cardiol · 2024
- Transcatheter Aortic Valve Replacement With the LOTUS Edge System: Early European Experience.
Armario X, Rosseel L, Kharbanda R, et al. · JACC Cardiovasc Interv · 2021Multicenter Study
- Optimal Oversizing Index Depending on Valve Type and Leakage-Proof Function for Preventing Paravalvular Leakage after Transcatheter Aortic Valve Implantation.
Ki YJ, Kang J, Lee HS, et al. · J Clin Med · 2020
- Outcome of transcatheter aortic valve replacement in bicuspid aortic valve stenosis with new-generation devices.
Gorla R, Casenghi M, Finotello A, et al. · Interact Cardiovasc Thorac Surg · 2021
- Quantitative Assessment of Acute Regurgitation Following TAVR: A Multicenter Pooled Analysis of 2,258 Valves.
Modolo R, Chang CC, Abdelghani M, et al. · JACC Cardiovasc Interv · 2020Comparative Study, Multicenter Study
- Nonuniform expansion of the LOTUS Edge intra-annular transcatheter aortic valve seen on intravascular ultrasound as a mechanism of prosthesis-patient mismatch.
Kaliczuk , Stokosa P, Dibrowski M, et al. · Kardiol Pol · 2021
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.